5-methylcytosine has been researched along with Bile Duct Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, JB; Dong, ZR; Fan, J; Gao, DM; Ke, AW; Qiu, SJ; Shi, GM; Sun, HC; Zhang, C; Zhang, PF; Zhou, J | 1 |
| Henson, R; Meng, F; Mize-Berge, J; Patel, T; Wehbe, H | 1 |
2 other study(ies) available for 5-methylcytosine and Bile Duct Cancer
| Article | Year |
|---|---|
Role of 5-hydroxymethylcytosine level in diagnosis and prognosis prediction of intrahepatic cholangiocarcinoma.
Topics: 5-Methylcytosine; Adolescent; Adult; Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cytosine; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis | 2015 |
Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression.
Topics: 5-Methylcytosine; Azacitidine; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Decitabine; DNA Methylation; ErbB Receptors; Humans; Interleukin-6; Promoter Regions, Genetic | 2006 |